Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for immunoglobulin light-chain amyloidosis (AL). A consensus panel was convened comprising 13 specialists actively involved in the treatment of patients with amyloidosis. Institutional criteria were submitted from each, and a consensus was developed defining each organ involved and the criteria for response. Specific criteria have been developed with agreed on definitions of organ and hematologic response as a result of discussions at the 10th International Symposium on Amyloid and Amyloidosis held in Tours, France, April 2004. These criteria now form the working definition of involvement and response for the purposes of future data collection and reporting. We report criteria that centers can now use to define organ involvement and uniform response criteria for reporting outcomes in patients with light-chain AL.
Gertz
Morie A
MA
Dysproteinemia Clinic, Mayo Clinic, Rochester, Minnesota 55905, USA. gertm@mayo.edu
Comenzo
Ray
R
Falk
Rodney H
RH
Fermand
Jean Paul
JP
Hazenberg
Bouke P
BP
Hawkins
Philip N
PN
Merlini
Giampaolo
G
Moreau
Philippe
P
Ronco
Pierre
P
Sanchorawala
Vaishali
V
Sezer
Orhan
O
Solomon
Alan
A
Grateau
Giles
G
D000682:Amyloid / Q000378:metabolism*; D000686:Amyloidosis / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy; D005602:France; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000378:metabolism*; D009928:Organ Specificity
D000682:Amyloid; D007147:Immunoglobulin Light Chains